SLN enters September with a striking split personality: the stock is up 31% over the past month and 9% on the week, yet short interest has climbed roughly 55% in the same 30-day window — a rare setup where momentum buyers and fresh bears are piling in simultaneously.
The positioning picture is more nuanced than the headline numbers suggest. Short interest has risen sharply — from about 1.57 million shares in late July to 2.43 million today — but the borrow market is not under any stress. Cost to borrow has collapsed to 0.38%, down nearly 79% on the week after briefly spiking toward 2% in early September. Availability is running at roughly 538% of short interest, meaning there are more than five shares available to borrow for every one already lent out. That is comfortably within the normal range and well above the 52-week tightest reading of 216%. Options traders are similarly relaxed: the put/call ratio of 0.34 is actually a touch below its 20-day average of 0.38, with the z-score barely negative. The borrow market and derivatives desk are not confirming the bears' conviction; they are shrugging.
The Street is squarely in the bull camp, though targets vary widely. Morgan Stanley raised its price target from $25 to $32 on August 11 — notably after the stock's big August 10 earnings pop — while maintaining its Overweight rating. HC Wainwright holds a Buy with a $75 target, a figure that looks stretched against the current price of $14.59 but reflects a longer-term pipeline view. Goldman Sachs has a Sell with a $3 target, a stale read from May 2025 that predates a significant repricing and should be treated with caution. Consensus skews bullish, with the mean target near $33 implying meaningful upside from here. Factor scores back the momentum narrative hard: EPS revision momentum ranks in the 98th percentile on a 30-day basis and 96th on 90 days, with EPS surprise in the 92nd percentile. The price-to-book multiple has expanded dramatically, up more than 6x over 30 days, which is characteristic of a pre-revenue biotech re-rating rather than fundamental cheapening.
The ownership register carries one notable tension. Richard Griffiths, an activist on the 13D register — a detail that is genuinely material — has cut his stake from 21.7% to 7.97%, filing a Schedule 13D/A on August 13. That is a substantial reduction. At the same time, Artal Group added 343,000 shares, Citadel added roughly 95,000, and Soleus Capital and Balyasny each built new positions of around 600,000 shares. The institutional story is therefore one of a large legacy holder reducing dramatically while a cohort of specialist healthcare and multi-strategy funds steps in — new money replacing old, not a broad exodus.
The earnings history adds context to current positioning. The August 10 print delivered a single-day gain of 23%, followed by a further 20% over five days — the catalyst that drove the recent re-rating. The most recent quarterly release on August 12 then gave back 5% on the day. The next event is not until November 10, leaving three months of space. The ORTEX short score of 44 is middling and has been drifting lower from around 46 at the start of the week, suggesting short-side pressure is neither building sharply nor retreating. Peers VKTX and PVLA are both up roughly 8% and 5% on the week respectively, so the RNAi and small biotech group is broadly catching a bid — SLN is not alone in its move.
What to watch next: whether the new institutional entrants hold their positions as the post-earnings momentum fades, whether the Griffiths 13D stake continues to decline toward the 5% disclosure threshold, and how the short interest trend develops once the latest borrow data settles after the recent cost-to-borrow volatility.
See the live data behind this article on ORTEX.
Open SLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
